✦ LIBER ✦

P679 LEVEL OF HEPATITIS B SURFACE ANTIGEN AND NOT HBV DNA LEVEL AFTER HBeAg SEROCLEARANCE IS PREDICTIVE OF HBsAg SEROCLEARANCE

✍ Scribed by Fung, J.; Lai, C.-L.; Wong, D.K.; Seto, W.-K.; Kopaniszen, M.; Yuen, M.-F.

Book ID: 122186440
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 59 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)60841-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

360 DEFINITION OF INACTIVE HEPATITIS B C

360 DEFINITION OF INACTIVE HEPATITIS B CARRIER BY SERUM HBSAG AND HBV DNA LEVELS – A LONG-TERM FOLLOW-UP STUDY ON HBSAG SEROCLEARANCE

✍ H.L.-Y. Chan; G.L-H. Wong; C.-H. Tse; H.-Y. Chan; V.W.-S. Wong 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 160 KB

P668 SERUM INTERLEUKIN 9 LEVEL AS A PRED

P668 SERUM INTERLEUKIN 9 LEVEL AS A PREDICTIVE MARKER OF SPONTANEOUS SEROCLEARANCE OF HEPATITIS B SURFACE ANTIGEN IN CHRONIC HEPATITIS B PATIENTS

✍ Yang, H.-I.; Lee, M.-H.; Liu, J.; Chien, Y.-C.; Chen, H.-Y.; Liu, C.-J.; Jen, C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 133 KB

P697 SERUM LEVELS OF HEPATITIS B SURFACE

P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS

✍ Marcellin, P.; Martinot-Peignoux, M.; Lau, G.; Liaw, Y.-F.; Messinger, D.; Rothe 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P653 RECLASSIFICATION OF IMMUNOTOLERANT

P653 RECLASSIFICATION OF IMMUNOTOLERANT CHRONIC HEPATITIS B INFECTION; DETECTION OF HBV VARIANTS WITH IMPLICATIONS FOR HBV DNA, HBsAg AND HBeAg LEVELS

✍ Rosenberg, G.; Bayliss, J.; Gaggar, A.; Kitrinos, K.; Subramanian, M.; Gane, E.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Prediction of response to entecavir ther

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels

✍ J. W. Shin; S. W. Jung; B. R. Park; C. J. Kim; J. B. Eum; B. G. Kim; I. D. Jeong 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.